The BLMK Medicines Optimisation Team

April 2026 – UPDATE

NHS Central East Integrated Care Board (ICB) was formed on 1 April 2026 and is the successor ICB to NHS Bedfordshire, Luton and Milton Keynes ICB, NHS Cambridgeshire and Peterborough ICB and the Hertfordshire part of NHS Hertfordshire and West Essex ICB. NHS Central East ICB had transferred to it the property, rights and liabilities of the predecessor organisations.

The actions and decisions of the predecessor organisation, including relevant clinical commissioning policies, relevant prescribing decisions and recommendations and relevant clinical pathways continue in effect. There are differences in places between some clinical commissioning policies, prescribing recommendations and pathways from the predecessor ICBs.

Clinical policies transferred to NHS Central East ICB from each of the relevant predecessor ICBs remain applicable to each part of the population for who they were originally created. These different policies will continue to apply to the relevant populations unless or until any new policy is adopted by the NHS Central East ICB (after public involvement if required).

We are in the process of developing a new NHS Central East ICB website for clinical commissioning policies, pathways and prescribing information. During this transition period, clinicians, providers, patients and the public can continue to access all legacy policies, prescribing recommendations, and pathways via the legacy ICB websites. Where legacy policies are superseded by new NHS Central East ICB policies, this will be clearly indicated on the relevant legacy policy and published on the new Central East website in advance of implementation.

If you have any questions or concerns do continue to contact your local teams at:

Hertfordshire and West Essex ICB                            ifr.hweicb@nhs.net

Bedfordshire, Luton and Milton Keynes ICB        Blmkicb.ifrservice@nhs.net

Cambridge and Peterborough ICB                             cpicb.clinpolicies@nhs.net

 

 

 

Updated Guidance for Continuous Glucose Monitors (CGM) in people with diabetes – Click Here

NEW PAGE: APPLIANCE PRESCRIBING IN BLMK

Quick Link: BLMK Position Statements
Quick Link: BLMK Antibiotics Guidance (this is an external link and will open in a new tab)

Medicines Optimisation is a part of the wider medicines optimisation agenda. It is an evidence-based approach to prescribing which balances the safety, tolerability, effectiveness, cost and simplicity of treatments.

Good medicines optimisation means that patients receive better, safer and more convenient care. It focuses on the prescribing of medicines ensuring patients get the best use from their medicines, working closely with clinicians to ensure the NHS gets the best value.

The team are also involved in the access to high-risk and high-cost medicines and working with secondary and tertiary care, mental health and community services to ensure these medicines are prescribed appropriately and safely.